Model Informed Dosing Regimen and Phase I Results of the Anti‐PD‐1 Antibody Budigalimab (ABBV‐181)

• Main Authors: John Powderly (Author), Alexander Spira (Author), Shunsuke Kondo (Author), Toshihiko Doi (Author), Jason J. Luke (Author), Drew Rasco (Author), Bo Gao (Author), Minna Tanner (Author), Philippe A. Cassier (Author), Anas Gazzah (Author), Antoine Italiano (Author), Diego Tosi (Author), Daniel E. Afar (Author), Apurvasena Parikh (Author), Benjamin Engelhardt (Author), Stefan Englert (Author), Stacie L. Lambert (Author), Sreeneeranj Kasichayanula (Author), Sven Mensing (Author), Rajeev Menon (Author), Gregory Vosganian (Author), Anthony Tolcher (Author)
• Format: Book
• Published: Wiley, 2021-01-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Budigalimab is a humanized, recombinant, Fc mutated IgG1 monoclonal antibody targeting programmed cell death 1 (PD‐1) receptor, currently in phase I clinical trials. The safety, efficacy, pharmacokinetics (PKs), pharmacodynamics (PDs), and budigalimab dose selection from monotherapy dose escalation...